Previous 10 | Next 10 |
Penny Stocks To Buy According To 5 Wall Street Analysts Today we look at a handful of penny stocks to buy, according to Wall Street analysts. It’s an interesting phenomenon when traders use ratings as part of their research methodologies. Sure, the so-called “smart mon...
Cabaletta Bio press release ( NASDAQ: CABA ): Q3 GAAP EPS of -$0.39 beats by $0.09 . As of September 30, 2022, Cabaletta had cash, cash equivalents and investments of $85.9 million, compared to $122.2 million as of December 31, 2021. Research and development expens...
PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third qua...
How Do Penny Stock Traders Follow The Money? One of the most exciting things about trading penny stocks is making quick money. But finding companies to add to your watch list can be easier said than done. There are plenty of trading strategies to use to do so, and one of the more po...
Time To Buy Penny Stocks After Analysts’ Latest Ratings? This article discusses a few more penny stocks to buy, according to Wall Street analysts. This is a continuation of our article “ 7 Penny Stocks To Buy According To Top Wall Street Analysts ,” & will l...
Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...
– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases – – CABA-201 Investigational New Drug (IND) application planned for the first ...
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translation...
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and...
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data thro...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...